Ensysce Biosciences, Inc.
NCM: ENSCLive Quote
📈 ZcoreAI Score
Our AI model analyzes Ensysce Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ENSC Z-Score →About Ensysce Biosciences, Inc.
Healthcare
Biotechnology
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
📊 Fundamental Analysis
Ensysce Biosciences, Inc. demonstrates a profit margin of -200.8%, which is below the sector average, suggesting competitive pressure.
The company recently reported 44.4% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -324.9%, which indicates that capital utilization is currently under pressure.
At a current price of $0.46, ENSC currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.31 - $4.85).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$4.31M
Trailing P/E
--
Forward P/E
-0.21
Beta (5Y)
1.14
52W High
$4.85
52W Low
$0.31
Avg Volume
6.23M
Day High
Day Low